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Abstract
Influenza viruses continuously circulate in the human population and escape recognition by virus neutralizing antibodies induced
by prior infection or vaccination through accumulation of mutations in the surface proteins hemagglutinin (HA) and neuramin-
idase (NA). Various strategies to develop a vaccine that provides broad protection against different influenza Aviruses are under
investigation, including use of recombinant (r) viral vectors and adjuvants. The replication-deficient modified vaccinia virus
Ankara (MVA) is a promising vaccine vector that efficiently induces B and T cell responses specific for the antigen of interest. It
is assumed that live vaccine vectors do not require an adjuvant to be immunogenic as the vector already mediates recruitment and
activation of immune cells. To address this topic, BALB/c mice were vaccinated with either protein- or rMVA-based HA
influenza vaccines, formulated with or without the saponin-based Matrix-M™ adjuvant. Co-formulation with Matrix-M signif-
icantly increased HAvaccine immunogenicity, resulting in antigen-specific humoral and cellular immune responses comparable
to those induced by unadjuvanted rMVA-HA. Of special interest, rMVA-HA immunogenicity was also enhanced by addition of
Matrix-M, demonstrated by enhanced HA inhibition antibody titres and cellular immune responses. Matrix-M added to either
protein- or rMVA-based HA vaccines mediated recruitment and activation of antigen-presenting cells and lymphocytes to the
draining lymph node 24 and 48 h post-vaccination. Taken together, these results suggest that adjuvants can be used not only with
protein-based vaccines but also in combination with rMVA to increase vaccine immunogenicity, which may be a step forward to
generate new and more effective influenza vaccines.
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Introduction
Influenza A (H1N1 and H3N2) and B viruses cause respira-
tory tract infections and are responsible for substantial mor-
bidity and mortality during seasonal epidemics, particularly in
patients at high risk, such as the elderly. Due to accumulation
of mutations in the surface proteins hemagglutinin (HA) and
neuraminidase (NA), the antigenic properties of the virus
change continuously, resulting in escape from recognition by
neutralizing antibodies induced by prior infection or vaccina-
tion [1–3]. Furthermore, avian influenza viruses of various
subtypes have been shown to infect humans sporadically
[4–6]. Since virus neutralizing antibodies to these viruses are
virtually absent in the human population, they are considered
to have pandemic potential.
Currently used inactivated influenza vaccines contain com-
ponents from seasonal influenza viruses and aim at the
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induction of HA-specific neutralizing antibodies [7, 8].
Despite annual assessment of virus strains to be included in
the seasonal influenza vaccine, a mismatch between circulat-
ing influenza viruses and the vaccine strains occasionally
occurs, resulting in reduced vaccine effectiveness [9–11].
Furthermore, novel tailor-made influenza vaccines need to
be developed momentarily in case of an influenza virus
pandemic. Clearly, there is a need for improved influenza
vaccines that can be produced rapidly and are highly immu-
nogenic, inducing broadly protective immunity to various in-
fluenza viruses.
Presently, novel vaccine targets, adjuvants, and delivery
systems are under investigation to develop “next-generation”
influenza vaccines. Recombinant viral vaccine vectors,
including modified vaccinia virus Ankara (MVA) and adeno-
viruses, can be used to drive expression of any antigen of
interest, resulting in efficient induction of antigen-specific B
and T lymphocyte responses [12, 13]. Particularly, MVA is
considered to be of interest since it has an excellent safety
record in humans, including immunocompromised individ-
uals [12–15]. Design and rescue of recombinant (r)MVA ex-
pressing one or more antigens are relatively easy and can be
performed rapidly, and large numbers of vaccine doses can be
produced [12]. Previously, several rMVAvaccines expressing
HA from various influenza viruses have been evaluated
in vitro and in vivo and have shown to be immunogenic and
capable of inducing protective immunity against homologous
and heterologous influenza virus infections [13].
Another approach to enhance influenza vaccine immuno-
genicity is the use of adjuvants [16]. Adjuvants such asMF59,
AS03, Alum, ISCOMATRIX®, and Matrix-M™ adjuvant
have successfully been evaluated in clinical trials in combina-
tionwith seasonal and pandemic influenza vaccines, including
inactivated whole virus, split-virion, virosomal, and virus-like
particle vaccines [17–23]. Furthermore, MF59 and AS03 have
been approved for use in a seasonal and pre-pandemic A
(H5N1) influenza vaccine, respectively [24]. Matrix-M adju-
vant, made of Quillaja saponins formulated with cholesterol
and phospholipids into nanoparticles, is known to augment
Th1 and Th2 responses, induce antibodies of multiple sub-
classes, enhance immune cell trafficking, and allow antigen
dose-sparing [25–31]. Importantly, Matrix-M-adjuvanted vac-
cines have been shown to have an acceptable safety profile in
clinical trials [21–23]. Compared to other adjuvants,
Matrix-M performed as well or better in combination with
influenza vaccines in mice [27, 32].
In contrast to protein-based vaccines, which are poorly im-
munogenic without adjuvant, vector-based vaccines are gen-
erally thought not to require adjuvants due to the intrinsic
adjuvant activity of the vector backbone [33]. However, re-
cently, it was shown that immunogenicity of malaria and Rift
Valley Fever virus antigens expressed from adenovirus or
MVAwas improved by addition of Matrix-M [34, 35]. In the
present study, we show that the immunogenicity of both HA
protein- and MVA-based influenza vaccines was enhanced by
Matrix-M adjuvant. Co-formulation of either vaccine with
Matrix-M adjuvant increased absolute immune cell numbers
and activation in the lymph node (LN) draining the site of
vaccination up to 48 h after injection.
Material and methods
Matrix-M™ adjuvant
Novavax’s proprietary Matrix-M™ adjuvant consists of two
individually formed 40-nm-sized particles, each with a differ-
ent and well-characterized saponin fraction (Fraction-A and
Fraction-C). The Matrix-A and -C particles are formed by
formulating purified saponin from the treeQuillaja saponaria
Molina with cholesterol and phospholipid [36].
Preparation of HA protein
Recombinant HA (H1N1, A/Puerto Rico/8/34 [PR8]) was pro-
duced in HEK293F cells as an amino-terminal His-tagged fusion
protein containing a linker sequence (PGGPGS) and mcaspase3
cleavage site (DELD) but lacking the HA transmembrane se-
quence. The secreted (His6-PGGPGSDELD)-HA protein was
purified by metal affinity chromatography. After mcaspase treat-
ment (E/S mass ratio 1/30), the protein solution was loaded on a
Superdex G200 gel filtration column and the HAwere fractions
pooled. Analysis by SDS-PAGE/CBB staining and western blot
showed that mature (cleaved) HA protein was obtained with a
purity of at least 90%.
Generation of rMVA-HA
rMVA expressing HA under control of the early/late vaccinia
virus promotor PsynII using the MVA clonal isolate F6 was
produced as previously described [37]. In short, the
codon-optimized HA nucleotide sequence (PR8, accession
number CY033577) was purchased from Baseclear B.V. and
rMVAwas prepared through mCherry-dependent plaque selec-
tion in chicken embryo fibroblasts (CEF). To generate a final
vaccine preparation, the virus was amplified in CEF, purified by
ultracentrifugation through 36% sucrose, and reconstituted in
120-mM NaCl and 10-mM Tris-HCl pH 7.4. rMVA-HA con-
structs were characterized by PCR, sequencing, plaque titration,
western blot, and in vitro infection of various cell types.
Vaccination of BALB/c mice
Specified pathogen-free female BALB/c mice (8–10 weeks
old) were purchased from Charles River Laboratories
(Germany). Animals were housed in Makrolon type 3 cages,
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had access to food and water ad libitum, and animal welfare
was observed daily. All experiments were conducted in
compliance with European guidelines and the protocol ap-
proved by an independent animal experimentation ethical
review committee (Uppsala djurförsöksetiska nämnd). Two
separate experiments were performed. In the first experi-
ment, mice (n = 5 or 8/group) received two vaccinations
with 108 plaque forming units (PFU) of rMVA-HA or 1
or 10 μg of HA, formulated with or without 5-μg
Matrix-M, at a 4-week interval. All vaccines were admin-
istered subcutaneously (s.c.) in 100 μL at the base of the
tail. Blood samples were obtained at day 21 and day 42.
Spleens were collected in PBS during necropsy. In the sec-
ond experiment, mice (n = 30/group) were immunized in-
tramuscularly (i.m.) in the hind leg with a volume of 50 μL
containing 108-PFU rMVA-HA or 10-μg HA, with or with-
out 5-μg Matrix-M. The inguinal LN draining the hind leg
muscle was col lec ted in PBS at 4 , 24, or 48 h
post-vaccination (n = 10/group/timepoint).
Detection of IgG1 and IgG2a HA-specific serum
antibodies
Quantification of HA-specific IgG1 and IgG2a antibodies was
performed by ELISA as described previously [27]. Briefly,
96-well Maxisorp microplates (Nunc) coated overnight
(O/N) at 4 °C with 50-ng/well HA protein in 0.05-M
carbonate/bicarbonate buffer (Sigma-Aldrich). Serum from
untreated mice and HA-positive mouse serum was used as
negative or positive control, respectively. IgG1 and IgG2a
anti-HA titers were calculated using a four-parameter logistic
equation (Softmax software, Molecular Devices). The inflec-
tion point of the titration curve (EC50 value) was taken as titer
value.
Hemagglutination inhibition (HI) assay
Sera were treated with a receptor-destroying enzyme (filtrate
ofVibrio cholerae) O/N at 37 °C followed by heat inactivation
for 1 h at 56 °C. Sera were titrated in a twofold serial dilution.
The HI assay was performed in duplicate following a standard
protocol with 1% turkey erythrocytes and four HA-units of
influenza virus PR8, as described previously [38].
Fluorospot analysis of antigen-stimulated
splenocytes
Single-cell suspensions from spleens of individual mice, pre-
pared as previously described [27], were seeded on filter plates
coated with anti-interleukin 2 (IL-2) and -interferon gamma
(IFN-γ) capture antibodies (Mabtech), at 0.25 × 106 cells/
well in culture medium (Roswell Park Memorial Institute,
Sigma-Aldrich) supplemented with 10% heat-inactivated fetal
bovine serum (Sigma-Aldrich) and 100-U/ml penicillin,
100-μg/ml s t reptomycin , and 2-mM L-glutamin
(Sigma-Aldrich), followed by stimulation with 0.5-μg/well
HA protein. Concanavalin A (Sigma-Aldrich) and culture me-
diumwere used as positive and negative controls, respectively.
Triplicate samples were incubated for 18 h at 37 °C and IL-2
and/or IFN-γ spots were developed according to the manufac-
turer’s instructions (Mabtech). Spots were detected using an
AID ELR02 ELISpot reader (Autoimmune Diagnostika
GmbH).
Flow cytometry analysis of immune cells in the dLN
Single-cell suspensions from the draining (d)LN, prepared as
described previously [27], were stained with FVS780 (BD
Biosciences) for 15 min at room temperature to exclude dead
cells during analysis. Cells were washed and resuspended in
FACS buffer (PBS with 0.5% bovine serum albumin, 2-mM
EDTA, and 0.1% NaN3,) and incubated for 20 min at 4 °C
with anti-mouse CD16/CD32 (2.4G2, BD Biosciences). 5 ×
105 cells/well were transferred to a 96-well microtiter plate
(Nunc) and incubated with anti-mouse CD86:FITC (GL1),
I-A/I-E:BV605 (M5/114), CD8a:BV650 (53-6.7), CD19:
PerCP-Cy5.5 (1D3), CD3e:PerCP-Cy5.5 (145-2C11),
Ly-6G:BV786 (1A8) (all BD Biosciences), CD169:
AlexaFluor647 (3D6.112), CD11c:BV650 (N418), Ly-6C:
APC (HK1.4), CD69:BV421 (H1.2F3), CD3e:PE
(145-2C11), F4/80:BV421 (BM8), CD11b:PE (M1/70),
CD49b:APC (DX5), and CD4:BV785 (RM4-5) (all Nordic
Biosite) for 30 min at 4 °C. Fluorescence minus one controls
were prepared for each antibody in all antibody panels at ac-
quisition timepoints. Samples were analyzed on FACSCelesta
with FACSDiva software (BD Biosciences).
Statistical analysis
Serological and cellular data were analyzed using one-way
ANOVA with Tukey’s post-test for multiple comparisons or
Kruskal-Wallis with Dunn’s multiple comparisons test when
applicable.
Results
Addition of Matrix-M adjuvant enhanced HA-specific
humoral responses
To assess HA-specific antibody responses after vaccination
with either protein- or rMVA-based vaccines with or without
Matrix-M adjuvant, mice were immunized at days 0 and 28.
At 21 days after the primary vaccination, HA-specific serum
antibody responses were detected in all groups. Strongest an-
tibody responses of both IgG1 and IgG2a were detected after
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vaccination with 10-μg HA adjuvanted with Matrix-M.
Without adjuvant, protein-based HA vaccines induced IgG1
and IgG2a responses inefficiently. After one immunization
with rMVA-HA, HA-specific IgG1 and IgG2a antibody re-
sponses were induced, which were not further enhanced by
Matrix-M addition (Fig. 1a–b). Fourteen days after the second
vaccination, HA-specific IgG1 and IgG2a levels were boosted
in all groups (Fig. 1c–d). Addition of Matrix-M to both HA
doses significantly increased IgG1 responses compared to
unadjuvanted HA or rMVA-HA vaccination with or without
adjuvant (Fig. 1c). The IgG2a responses after the second vac-
cination were comparable between adjuvanted HA groups and
both rMVA-HA vaccine groups and were elevated compared
to the unadjuvanted HA group (Fig. 1d). Use of Matrix-M did
not increase IgG1 or IgG2a responses after the second vacci-
nation with rMVA-HA.
Next, HI antibody titers were determined, which is consid-
ered a good proxy for the virus-neutralizing antibody re-
sponse. In contrast to the IgG1 and IgG2a responses detected
after primary vaccination, mice vaccinated with rMVA-HA
displayed significantly elevated HI titers compared to those
vaccinated with HA, regardless of antigen dose and use of
adjuvant (Fig. 2a). After booster vaccination, HI titers were
detected in mice receivingMatrix-M-adjuvanted HA, whereas
lower HI titers were detected in only two out of five mice
receiving unadjuvanted HA. After two immunizations,
adjuvanted HA induced similar HI titers as rMVA-HA vacci-
nation (Fig. 2b). Of special interest, higher HI titers were
observed in mice vaccinated with adjuvanted rMVA-HA com-
pared to mice that received unadjuvanted rMVA-HA.
Addition of Matrix-M adjuvant enhanced HA-specific
cellular responses
To investigate HA-specific T lymphocyte responses after
booster vaccination, splenocytes were stimulated with HA
protein and the number of IL-2 and/or IFN-γ producing cells
was measured. Matrix-M-adjuvanted HA and rMVA-HA,
with or without adjuvant, induced significantly more IL-2
and/or IFN-γ producing splenocytes than HA alone.
Unadjuvanted HA hardly induced any IL-2 and/or IFN-γ
splenocyte responses (Fig. 3a–c). In contrast, co-formulation
of HAwith Matrix-M resulted in higher IL-2 responses com-
pared to rMVA-HA, adjuvanted or not, whereas rMVA-HA
induced higher IFN-γ responses compared to adjuvanted HA
(Fig. 3a–c). Mice vaccinated with Matrix-M-adjuvanted
rMVA-HA displayed stronger IL-2, IFN-γ, and IL-2/IFN-γ
double-positive responses compared those receiving
Fig. 1 HA-specific antibody
responses induced after
vaccination with HA protein or
rMVA-HAwith or without
Matrix-M adjuvant IgG1 (a) and
IgG2a (b) HA-specific antibody
responses 21 days after the
primary vaccination. c–d IgG1
and IgG2a HA-specific antibody
responses 14 days after the
booster vaccination. IgG1 (a, c) or
IgG2a (b, d) serum antibodies
were detected by ELISA using
purified HA protein and anti-
IgG1 or anti-IgG2a HRP-
conjugated antibodies. Data is
shown as mean ± 95% confidence
interval (CI). *p < 0.05;
**p < 0.01; ***p < 0.001;
****p < 0.0001. MM=Matrix-M
adjuvant
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unadjuvanted rMVA-HA, although the differences were ex-
clusively statistically significant for the IL-2 response
(Fig. 3a–c).
Matrix-M-adjuvanted vaccines increased cell numbers
in the dLN
It is known that injection of Matrix-M adjuvant alone leads to
influx of several types of immune cells to the dLN at early
timepoints, and this effect has been associated with increased
antigen-specific immune responses [27, 28]. As addition of
Matrix-M to either protein- or MVA-based vaccines increased
both HA-specific humoral and cellular immune responses, we
wanted to evaluate the early cellular immune response in the
dLN to explore possible differences when combining the ad-
juvant with the respective vaccine type. Mice were vaccinated
i.m. with HA or rMVA-HA, with or without Matrix-M, and
dLNs were collected 4, 24, and 48 h post-vaccination. At 4 h
post-vaccination, the mean number of total cells in the dLN of
all vaccine groups was similar (Fig. 4a). In contrast, after 24
and 48 h, the total cell count per dLN of mice vaccinated with
adjuvanted HA or rMVA-HA showed more than a twofold
increase compared to the unadjuvanted groups (Fig. 4a). Of
note, although not as strong as the adjuvanted vaccines, vac-
cination with unadjuvanted rMVA-HA also resulted an in-
crease in cell count per dLN compared to HA alone.
The relative contribution of different cell populations
(Supplementary Fig. 1) to the total cell number in each dLN
(n = 10/group) was determined. At all timepoints, regardless
of vaccine type or use of adjuvant, CD4+ T lymphocytes com-
prised the largest proportion of the total cell population,
followed by CD8+ T and B lymphocytes (Fig. 4b). No sig-
nificant difference in the percentage of neutrophils, macro-
phages, NK cells, or DCs was observed (Fig. 4b). In con-
trast, mice vaccinated with Matrix-M-adjuvanted HA or
rMVA-HA and to a lesser extent, unadjuvanted rMVA-HA
showed a strong increase in proportion and total number of
monocytes in the dLN over time, indicating recruitment
Fig. 2 Induction of HA-specific
HI antibody responses after
vaccination with rMVA-HA
adjuvanted with Matrix-M HI
serum antibody responses against
influenza virus A/Puerto Rico/8/
34 (H1N1) was measured 21 days
after the primary (a) or 14 days
after the booster (b) vaccination.
Data is shown as mean ± 95% CI.
*p < 0.05; **p < 0.01;
***p < 0.001. MM=Matrix-M
adjuvant
Fig. 3 Enhanced HA-specific splenocyte responses by Matrix-M-
adjuvanted vaccine spleens obtained 14 days after the booster
vaccination were stimulated with purified HA protein and the number
of IL-2 (a), IFN-γ (b), and IL-2/IFN-γ (c) producing splenocytes was
determined in spot forming units (SFU)/106 cells by Fluorospot assay.
Samples were tested in triplicate. The mean ± 95% CI of each group is
indicated. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. MM=
Matrix-M adjuvant
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and/or proliferation compared to HA alone (Fig. 4b–c).
Notably, the number of medullary sinus macrophages
(CD169+F4/80+) was increased by Matrix-M-adjuvanted
HA and rMVA-HA at 24 and 48 h after vaccination com-
pared to unadjuvanted vaccine preparations (Fig. 4d). At
48 h, the unadjuvanted rMVA-HA group also showed an
increase in medullary sinus macrophages compared to the
unadjuvanted HA group, but to a lesser extent than the
adjuvanted vaccines.
Cell activation in the dLN after vaccination
with Matrix-M-adjuvanted vaccine preparations
Activation of different cellular subsets was investigated by
measuring expression of CD69 (early activation marker
[39]), CD86 (T lymphocyte co-stimulatory signal [40]), and/
orMHC class II (often upregulated on antigen-presenting cells
(APC) after activation). Expression of both CD69 and CD86
was upregulated on DCs, monocytes, and B lymphocytes 24
and 48 h after vaccination with either Matrix-M-adjuvanted
HA or rMVA-HA compared to the respective unadjuvanted
vaccine preparation (Fig. 5a–b). Unadjuvanted rMVA-HA al-
so induced an increase in CD69+ and CD86+ DCs, monocytes,
and B lymphocytes compared to unadjuvanted HA at 24 and
48 h post-vaccination, however, only to a limited extent com-
pared to the adjuvanted vaccines (Fig. 5a–b). In addition to the
increase in CD69+ and CD86+ APCs, MHC class II expres-
sion in DCs was elevated at 24 and 48 h post-vaccination with
the adjuvanted vaccine preparations (Fig. 5c). CD69 expres-
sion was also assessed for T lymphocytes and NK cells. The
number of CD69+ NK cells and T lymphocytes was signifi-
cantly increased after vaccination with Matrix-M-adjuvanted
HA, or rMVA-HA, compared to their unadjuvanted counter-
parts (Fig. 6a–c).
Altogether, rMVA-HA induced relatively more activation,
recruitment, and/or proliferation of APC and lymphocytes
compared to unadjuvanted HA. However, addition of
Matrix-M adjuvant to either protein- or MVA-based HA vac-
cines significantly increased activation and recruitment and/or
proliferation for both vaccine preparations.
Fig. 4 Matrix-M-adjuvanted influenza vaccines induce influx of immune
cells in the dLN with maintained composition of cellular subsets except
for an increased monocyte population. a The total number of cells per
dLN. b Contribution (%) of the indicated cellular subsets in the dLN was
measured by flow cytometry at 4, 24, or 48 h after i.m. vaccination. c–d
Total cell count of CD11b+Ly6C+ monocytes (c) and CD169+F4/80+
medullary sinus macrophages (d) were determined by flow cytometry.
Data are shown as mean of 10 mice per group. *p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001. MM=Matrix-M adjuvant
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Discussion
Adjuvants increase vaccine immunogenicity via different
mechanisms, including antigen delivery and general activa-
tion of innate immune responses [41]. Although use of adju-
vants for protein-based vaccines is well established and essen-
tial for efficient immune responses, addition of adjuvants to
vector-based influenza vaccines has not been previously stud-
ied. Here, the immunogenicity of influenza virus HA and
rMVA-HA vaccines was tested in the presence and absence
of Matrix-M adjuvant. Even if unadjuvanted rMVA-HA was
more immunogenic than unadjuvanted HA, co-formulation of
either vaccine preparation with Matrix-M enhanced
HA-specific immune responses and increased the cell number
and activation in the dLN.
For induction of proper HA-specific antibody responses of
IgG1 (indicative of Th2 responses) or IgG2a (indicative of
Th1 responses) subclasses, addition of Matrix-M adjuvant to
Fig. 5 Increased activation of APCs in the dLN 24 and 48 h after
vaccination with Matrix-M-adjuvanted influenza HA vaccines. a–b The
number of CD69+ or CD86+ DCs, monocytes, and B lymphocytes
recruited to the dLN was measured by flow cytometry 4, 24, and 48 h
after i.m. injection of the respective vaccine. c The mean fluorescence
intensity (MFI) of MHC class II of on DCs, monocytes, and B
lymphocytes in the dLN was measured by flow cytometry 4, 24, and
48 h post-injection. Data are shown as mean of 10 mice per group.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. MM=Matrix-M
adjuvant
Fig. 6 Increased number of activated NK- and T lymphocytes in the dLN
at 24 and 48 h post-vaccination with Matrix-M-adjuvanted influenza HA
vaccines The number of CD69+ NK cells (a), CD4+ (b), and CD8+ (c) T
lymphocytes in the dLN was measured by flow cytometry 4, 24, and 48 h
after i.m. injection of the respective vaccines. Data are shown as mean of
10 mice per group. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
MM=Matrix-M adjuvant
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HAwas required, but not to rMVA-HA. After two immuniza-
tions, adjuvanted HA induced significantly higher IgG1 anti-
body responses than rMVA-HA, whereas IgG2a antibody re-
sponses were similar. This is in line with previously published
data showing that MVA-based vaccines preferentially induce
Th1 responses [12, 13]. The observed potentiating effect of
Matrix-M on the IgG2a antibody responses has been shown
previously with various vaccine preparations in mice [27, 29,
31]. Induction of potent IgG2a responses bares relevance, as
murine IgG2 has key immunological effector functions, such
as enhanced FcγR binding important for protection against
viral infection [42]. Accordingly, passive immunization with
HA stalk-specific IgG2a antibodies has shown to protect mice
against influenza virus infection, while HA stalk-specific
IgG1 antibodies did not [43]. To induce functional antibodies,
a single vaccination with rMVA-HAwas sufficient for gener-
ating acceptable HI antibody titers, whereas for HA, regard-
less of adjuvantation, two vaccinations were required. This
may reflect a better conformational integrity of HA expressed
in vivo by rMVA-HA. Strikingly, addition of Matrix-M adju-
vant to the rMVA-HA vaccine significantly increased the HI
antibody response after both prime and booster vaccination, in
spite of the adjuvant having no clear effect on the HA-specific
IgG1 and IgG2a titers for the rMVA-HA vaccine.
Addition of Matrix-M adjuvant to HA potentiated
HA-specific IFN-γ and IL-2/IFN-γ cellular responses signif-
icantly compared to HA alone, in concordance with previous
studies [29–31, 44]. Interestingly, mice vaccinated with
rMVA-HA showed stronger IFN-γ responses than those vac-
cinated with adjuvanted HA. The rMVA-HA-induced cellular
responses could be even further increased by addition of
Matrix-M. Although the phenotype of the responding cells
was not determined, these are most likely CD4+ T lympho-
cytes as exogenous HA protein was used for stimulation.
It was previously shown in mice that injection with
Matrix-M adjuvant alone led to increased numbers of activat-
ed immune cells in the dLN compared to PBS or other adju-
vants [27, 28]. Here, the absolute number of cells in the dLN
of mice vaccinated with adjuvanted HA or rMVA-HA vac-
cines was significantly higher compared to mice vaccinated
with unadjuvanted vaccines 24 and 48 h post-vaccination,
indicative of proliferation and/or recruitment. The dLN cell
composition was stable, except for an increase in monocytes
after vaccination with adjuvanted vaccine preparations.
Recruited monocytes could mature into DCs and/or macro-
phages in situ and subsequently act as professional APC
[45], potentially improving vaccine efficacy. This could also
be the effect of the increase in CD169+ medullary sinus mac-
rophages, also detected in the dLN after injection with
Matrix-M-adjuvanted vaccines. Recently, CD169+ macro-
phages were shown to be important for the adjuvant properties
of the saponin-based adjuvant QS21 [46]. CD169+ macro-
phages have been shown to transport antigens trapped inside
the LN follicle to B lymphocytes and can cross-present anti-
gen directly to CD8+ T lymphocytes [47–49]. Thus, the in-
crease in CD169+ macrophages may play a role in the im-
proved adap t ive immune responses induced by
Matrix-M-adjuvanted vaccines.
Vaccination with unadjuvanted rMVA-HA induced a rela-
tive increase in monocytes accompanied by increased activa-
tion of CD86+ DC, CD86+ B lymphocytes, and CD169+
macrophages, confirming that MVA has intrinsic adjuvant
properties. Of interest, it was recently shown that APCs can
be infected by MVA and detected in the dLN of various spe-
cies including non-human primates [50]. Thus, the observed
adjuvant capacities of MVAmay be explained by direct infec-
tion of APCs, which travel to the dLN, shaping the immune
response.
In conclusion, our results show that influenza vaccines
based on recombinant HA protein or rMVA-HA can be poten-
tiated by Matrix-M adjuvant, resulting in improved humoral
and cellular responses. This is potentially mediated by recruit-
ment and activation of immune cells in the dLN. Combination
of a vector-based vaccine with Matrix-M adjuvant might
prove a promising step towards next-generation influenza
vaccines.
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